Who owns GSK
1,001 institutions reported holding GSK for 2026Q1, together 9.2% of the company, more than the 974 a quarter earlier.
1,001
Institutions reporting a position · as of 2026Q1 · up from 974 the quarter before
- Shares held by institutions
- 371.4M
Shares held by institutions · 9.2% of the company · long US equity positions only, as reported on Form 13F
- Reported value
- $20.5B
Reported value · at 2026-03-31 prices, not today's
- Top 5 holders
- 4.9%
Top 5 holders · of the whole company, between five filers
Details›
- Reporting quarter2026-03-31
- 2026Q1
- Quarters on record
- 52
- New positions
- 130
- Positions exited
- 106
- Added to
- 282
- Reduced
- 348
- Top 10 holdersof the company
- 6.1%
| Quarter | Filers | Shares | Reported value |
|---|---|---|---|
| 2026Q1 | 1,001 | 371.4M | $20.5B |
| 2025Q4 | 974 | 395.0M | $19.5B |
| 2025Q3 | 875 | 381.6M | $16.5B |
| 2025Q2 | 872 | 373.0M | $14.3B |
| 2025Q1 | 841 | 362.9M | $14.1B |
| 2024Q4 | 829 | 338.5M | $11.5B |
| 2024Q3 | 889 | 307.7M | $12.6B |
| 2024Q2 | 874 | 310.0M | $11.9B |
| 2024Q1 | 896 | 308.9M | $13.2B |
| 2023Q4 | 880 | 289.2M | $10.7B |
| 2023Q3 | 834 | 284.1M | $10.3B |
| 2023Q2 | 814 | 276.9M | $9.87B |
| 2023Q1 | 800 | 270.7M | $9.65B |
| 2022Q4 | 805 | 277.2M | $9.74B |
| 2022Q3 | 737 | 266.5M | $7.86B |
| 2022Q2 | 890 | 340.3M | $15.7B |
| Holder | Shares | % of company | Value |
|---|---|---|---|
| FMR LLC | 67.7M | 1.7% | $3.73B |
| Dodge & Cox | 58.7M | 1.4% | $3.24B |
| Fisher Asset Management, LLC | 34.5M | 0.85% | $1.91B |
| PRIMECAP MANAGEMENT CO/CA/ | 25.2M | 0.62% | $1.39B |
| ACADIAN ASSET MANAGEMENT LLC | 11.8M | 0.29% | $651M |
| WELLINGTON MANAGEMENT GROUP LLP | 11.7M | 0.29% | $647M |
| MORGAN STANLEY | 11.0M | 0.27% | $609M |
| GOLDMAN SACHS GROUP INC | 9.6M | 0.24% | $529M |
| JTC Employer Solutions Trustee Ltd | 9.0M | 0.22% | $499M |
| ROYAL BANK OF CANADA | 7.5M | 0.18% | $414M |
SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.
reading the register…
Drug Manufacturers - General
Ranks #8 of 16 by Smart Score